169 related articles for article (PubMed ID: 20179914)
1. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 May; 66(5):497-502. PubMed ID: 20179914
[TBL] [Abstract][Full Text] [Related]
2. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
5. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2011 May; 71(5):718-26. PubMed ID: 21204914
[TBL] [Abstract][Full Text] [Related]
6. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 Sep; 66(9):865-70. PubMed ID: 20496145
[TBL] [Abstract][Full Text] [Related]
7. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
[TBL] [Abstract][Full Text] [Related]
9. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
[TBL] [Abstract][Full Text] [Related]
11. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
Buczko W; Hermanowicz JM
Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
[TBL] [Abstract][Full Text] [Related]
13. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
14. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
[TBL] [Abstract][Full Text] [Related]
15. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2010 Sep; 88(3):339-42. PubMed ID: 20664534
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
[TBL] [Abstract][Full Text] [Related]
17. Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
Hypertension; 2011 Apr; 57(4):852-8. PubMed ID: 21321303
[TBL] [Abstract][Full Text] [Related]
18. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
Huang HL; Vaidyanathan S; Yeh CM; Bizot MN; Dieterich HA; Dole WP; Howard D
Curr Med Res Opin; 2008 Sep; 24(9):2449-56. PubMed ID: 18662494
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.
Hong Y; Dingemanse J; Mager DE
Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]